Advertisement

Topics

$TGTX beginning all in-house triple combination therapy trial in CLL & B Cell lymphoma. U2 + 1701 BTK inhibitor. Greatly overlooked strategic advantage of controlling such promising assets across a range of classes. UNITY CLL just the start. https://clini

15:39 EDT 14 Sep 2018 | tgtxdough

beginning all in-house triple combination therapy trial in CLL & B Cell lymphoma. U2 + 1701 BTK inhibitor. Greatly overlooked strategic advantage of controlling such promising assets across a range of classes. UNITY CLL just the start. https://clinicaltrials.gov/ct2/show/NCT03671590?term=ublituximab&lupd_s=09%2F14%2F2018&rank=1 …

Original Article: $TGTX beginning all in-house triple combination therapy trial in CLL & B Cell lymphoma. U2 + 1701 BTK inhibitor. Greatly overlooked strategic advantage of controlling such promising assets across a range of classes. UNITY CLL just the start. https://clini

NEXT ARTICLE

More From BioPortfolio on "$TGTX beginning all in-house triple combination therapy trial in CLL & B Cell lymphoma. U2 + 1701 BTK inhibitor. Greatly overlooked strategic advantage of controlling such promising assets across a range of classes. UNITY CLL just the start. https://clini"

Advertisement
Quick Search
Advertisement
Advertisement